Decreased viability in neuroblastoma (Li et al., 2018, p. 2) and glioblastoma (Sun et al., 2019), and invasion capacity in breast carcinoma (Zhuang et al., 2020) cells by RRM2 inhibition were defined previously. This evidence concerns the gene RRM2 and glioblastoma.